Zohydro ER is prescribed to manage pain severe enough to need daily, around-the-clock, long-term treatment, where other therapy options do not work.
However, Zohydro ER had A LOT of healthcare professionals up in arms when it received approval by the FDA. As it was initially approved, Zohydro ER was a potent narcotic, but not formulated to prevent or discourage abuse.
Most narcotics that are currently available have been formulated to discourage patients from taking them in ways that are not intended by the manufacturer. Some examples include Oxycontin (oxycodone), Opana ER (oxymorphone), Embeda (morphine/naltrexone), and Exalgo (hydromorphone).
Zohydro ER will now be formulated with a technology known as BeadTek. According to Zogenix, the manufacturer of Zohydro ER, BeadTek is designed to provide abuse-deterrent properties without changing how the medication works when taken correctly.
Zogenix received approval by the FDA on January 30, 2015 for the new formulation. The new Zohydro ER is expected to be available in the second quarter of 2015 for all strengths, and without disruption to those who are currently taking the medication.
For more information refer to this news release from Zogenix.